多参数MRI可见多病灶前列腺癌靶向活检方案优化:是否应靶向所有可疑区域?
该研究基于两家三级转诊中心2013至2019年312例前列腺mpMRI显示两个可疑病灶的男性队列,评估在系统活检基础上对次要病灶(SL)额外靶向活检的诊断增益。结果显示,在系统活检联合主要病灶靶向活检时,额外靶向SL仅使csPCa检出率增加2%(p=0.12),且SL的PI-RADS评分或靶向针数均与csPCa检出无关,提示可安全省略对次要病灶的靶向活检。
要点
- 系统活检联合主要病灶靶向活检时,额外靶向次要病灶仅提高csPCa检出2%。
- 次要病灶的PI-RADS评分和靶向针数均与csPCa检出无显著关联。
- 年龄、PSA、前列腺体积和主要病灶PI-RADS是csPCa检出的独立预测因素。
核心结论
- 在系统活检联合主要病灶靶向活检的情况下,额外靶向次要病灶对csPCa检出无显著获益,可安全省略。
研究设计与样本
- 回顾性队列研究,纳入两家三级转诊中心2013至2019年间312例mpMRI显示两个可疑病灶并接受每个病灶靶向活检及同期系统活检的男性。
主要发现
- 全部病灶靶向活检的csPCa检出率为44%,主要病灶和次要病灶靶向活检分别为39%和23%。
- 仅系统活检、仅主要病灶靶向活检和仅次要病灶靶向活检发现的csPCa比例分别为5%、6%和2%。
- 系统活检联合主要病灶靶向活检的csPCa检出率为47%,额外增加次要病灶靶向活检仅提高2%(p=0.12)。
- 多变量分析中,次要病灶的PI-RADS评分和靶向针数均与csPCa检出增加无关(所有p>0.3)。
- 年龄(OR: 1.07)、PSA(OR: 1.07)、前列腺体积(OR: 0.98)和主要病灶PI-RADS(OR: 2.36)与csPCa检出独立相关(所有p<0.01)。
临床怎么用
- 对于mpMRI显示多个可疑病灶的男性,在充分系统活检联合主要病灶靶向活检时,可考虑省略对次要病灶的靶向活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To assess the diagnostic added value of sampling secondary lesions at prostate mpMRI (SL) in addition to index lesion (IL) in detecting significant prostate cancer (csPCa) when also systematic biopsy (SBx) is performed. METHODS: We relied on a cohort of 312 men with two suspicious lesions at prostate mpMRI who underwent subsequent targeted biopsy of each lesion (TBx) and concomitant SBx at two tertiary-referral centers between 2013 and 2019. The study outcome was the added value of targeting SL (i.e., the one with a lower PI-RADS score and/or the smaller size compared to IL) in the detection of csPCa. To this aim, we compared different biopsy strategies (SBx + overall TBx vs SBx + IL-targeted biopsy vs SBx + SL-targeted biopsy) and assessed whether SL features could be correlated with detection of csPCa at overall TBx in a multivariable logistic regression model (MVA). RESULTS: Overall, 44% of men had csPCa at TBx of all lesions while 39% and 23% of men had csPCa found in IL and SL, respectively. The rate of csPCa found at SBx, IL-TBx, and SL-TBx only was 5%, 6%, and 2%, respectively. The detection rate of csPCa for SBx + IL-TBx was 47%. The addition of SL-TBx increased csPCa detection by only 2% (p = 0.12). At MVA, neither PI-RADS of SL nor the number of cores targeting SL was associated with an increased detection of csPCa (all p > 0.3). Conversely, age (OR: 1.07), PSA (OR: 1.07), prostate volume (OR: 0.98), and PI-RADS of the IL (OR: 2.36) were independently associated with csPCa detection at TBx (all p < 0.01). CONCLUSIONS: There is no significant benefit in terms of csPCa detection when an adequate SBx is performed in combination with IL-TBx in patients with multiple mpMRI lesions. In these men target biopsy of secondary lesions can be safely omitted.
引用
- Stabile A, Barletta F, Motterle G, et al. Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series. Prostate Cancer Prostatic Dis. 2021. PMID: 33941867. doi:10.1038/s41391-021-00371-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。